BioSpace News Archive

According to the report, the global Fetal Bovine Serum Market was valued at US$ 0.9 Bn in 2018 and is anticipated to expand at a CAGR of 5.8% from 2019 to 2027

A quality-based program is vital in every compounding pharmacy to ensure that each preparation is compounded properly and is stable for its expected duration of use.

EyePoint Pharmaceuticals, Inc. announced the presentation of data supporting YUTIQ® 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye.

Tonix Pharmaceuticals Holding Corp. announced that preclinical results of TNX-1900 will be presented in a poster at the American Academy of Neurology’s first-ever Sports Concussion Conference.

Mateon Therapeutics announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of its EdgePoint AI, Inc..

VASCEPA showed significant reduction in coronary revascularization, including coronary stenting and cardiac bypass surgery, in prespecified and post hoc analyses of landmark REDUCE-IT study

Progressive Care Inc. is pleased to announce operational performance data for June 2020, along with preliminary fiscal Q2 performance data, both of which demonstrate a continued robust trend of growth in sales, prescriptions, 340B income, and COVID- 19 testing service revenues.

PolyPid Ltd. announced that Dr. Anthony Senagore, colorectal surgeon and a medical advisor to PolyPid, is presenting a recorded video presentation today highlighting previously presented key results from PolyPid’s successfully completed Phase 2 clinical trial of D-PLEX100 for the prevention of surgical site infections in abdominal surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions.

Palatin Technologies, Inc. announced that it has mutually terminated the January 2017 license agreement which granted AMAG Pharmaceuticals exclusive North American rights to market Vyleesi®, the first and only on demand treatment for pre-menopausal women suffering from acquired, generalized, hypoactive sexual desire disorder, a condition affecting one in ten premenopausal women.

Company’s ultra-sensitive Simoa® technology powers more than 50 posters and presentations on display during this year’s virtual program; attendees can be among the first to experience Simoa p-tau181 assay for improved study of Alzheimer’s disease and visit virtual exhibitor booth